AMCP Applauds Introduction of the "Pharmaceutical Information Exchange (PIE) Act of 2017"
Alexandria, Va., April 10, 2017 — The Academy commends Rep. Brett Guthrie (R-KY) for introducing H.R.2026, the "Pharmaceutical Information Exchange (PIE) Act of 2017". The bill aims to improve patient access to emerging medication therapies by clarifying the scope of permitted health care economic and scientific information communications between biopharmaceutical manufacturers and population health decision makers.
The bill incorporates AMCP's multi-stakeholder consensus recommendations to allow biopharmaceutical manufacturers to proactively share clinical and economic information with population health decision makers on emerging therapies in advance of Food and Drug Administration (FDA) approval, an area that is significantly restricted by current federal laws and FDA regulations.
AMCP CEO Susan A. Cantrell, RPh, CAE, said, “AMCP thanks Rep. Guthrie for his leadership in championing this very important issue. The PIE Act will help AMCP members better care for the patient populations they serve by aiding in forecasting and budgeting, enabling the implementation of value-based contracts, and expediting coverage decisions for emerging therapies granted breakthrough designation immediately upon FDA approval. AMCP is proud to have led on this issue on behalf of our members.”
AMCP will work in the weeks and months ahead to build bipartisan support for passage of this legislation.